

# Paolo Manca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4221864/publications.pdf>

Version: 2024-02-01

24  
papers

425  
citations

840776

11  
h-index

752698

20  
g-index

24  
all docs

24  
docs citations

24  
times ranked

901  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exosomes as diagnostic and predictive biomarkers in lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, S1373-S1382.	1.4	90
2	Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer. <i>ESMO Open</i> , 2018, 3, e000398.	4.5	79
3	Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. <i>Oncotarget</i> , 2017, 8, 20113-20121.	1.8	36
4	Determinants of bone specific metastasis in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 59-66.	4.4	18
5	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		18
6	Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. <i>British Journal of Cancer</i> , 2022, 126, 449-455.	6.4	15
7	Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2435.	3.7	15
8	The value of immunotherapy in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 35-43.	3.1	14
9	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2505-2514.	7.0	14
10	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 161, 90-98.	2.8	13
11	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	2.8	12
12	EGFR Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1561-1569.	6.3	12
13	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2021, 20, 314-317.	2.3	12
14	Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib. <i>Oncotarget</i> , 2017, 8, 59986-59990.	1.8	11
15	Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies. <i>Translational Lung Cancer Research</i> , 2020, 9, 2581-2598.	2.8	11
16	Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers. <i>Journal of Immunology</i> , 2022, 208, 1362-1370.	0.8	11
17	Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy. <i>JCO Precision Oncology</i> , 2022, 6, e2200037.	3.0	11
18	Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. <i>JCO Precision Oncology</i> , 2020, 4, 1339-1349.	3.0	10

#	ARTICLE	IF	CITATIONS
19	ROS-1 Rearrangements in Circulating Tumor Cells. <i>Journal of Thoracic Oncology</i> , 2018, 13, e71-e72.	1.1	9
20	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. <i>JCO Precision Oncology</i> , 2022, 6, e2200015.	3.0	8
21	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECURSE trial. <i>Tumori</i> , 2021, 107, 353-359.	1.1	5
22	Bone-Modifying Agents and Anticancer Agents with Bone Effects. , 2019, , 13-25.		1
23	Ceritinib: an orphan drug for ALK positive non-small cell lung cancer with robust clinical evidence. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 991-997.	0.8	0
24	Novel Biomarkers Predicting the Development of Bone Metastasis in Early Breast Cancer. , 2019, , 363-370.		0